Pharmaceutical composition for treatment or prevention of stress urinary incontinence or mixed urinary incontinence, and screening method for compounds contained in the pharmaceutical composition
The present invention provides a pharmaceutical composition for treating or preventing urinary incontinence based on a novel mechanism of action, and a method for screening a compound contained as an active ingredient in the pharmaceutical composition. The present invention relates to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, which contains a compound having a melatonin receptor activating action as an active ingredient. Examples of the active ingredient include melatonin, ramelteon, agomelatin, tasimelteon, TIK-301 and the like. Also effective for pharmaceutical composition for treatment or prevention of stress urinary incontinence or mixed urinary incontinence comprising the steps of measuring activation of melatonin receptor, measuring contraction of isolated urethra, measuring urethral pressure, etc. The present invention relates to a method for screening a compound contained as a component. [Selection] Figure 6【課題】新規な作用機序に基づく尿失禁の治療又は予防用医薬組成物、及び、当該医薬組成物に有効成分として含有される化合物のスクリーニング方法を提供する。【解決手段】本発明は、メラトニン受容体活性化作用を有する化合物を有効成分として含有する、腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物に関する。当該有効成分として、メラトニン、ラメルテオン、アゴメラチン、タシメルテオン又はTIK-301等が挙げられる。また、メラトニン受容体の活性化を測定する工程、摘出尿道の収縮を測定する工程、尿道内圧を測定する工程などからなる腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物に有効成分として含有される化合物のスクリーニング方法に関する。【選択図】図６
